• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Enhancing Predictive Models for Ustekinumab Effectiveness in Crohn's Disease: Suggestions for Improved Clinical Applicability [Letter].

作者信息

Hu Chencheng, Yu Tengjiang, Yang Xiangdong

机构信息

College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou City, Sichuan Province, People's Republic of China.

The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan Province, People's Republic of China.

出版信息

J Inflamm Res. 2024 Dec 28;17:11755-11756. doi: 10.2147/JIR.S510503. eCollection 2024.

DOI:10.2147/JIR.S510503
PMID:39749004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11694019/
Abstract
摘要

相似文献

1
Enhancing Predictive Models for Ustekinumab Effectiveness in Crohn's Disease: Suggestions for Improved Clinical Applicability [Letter].增强乌司奴单抗治疗克罗恩病有效性的预测模型：提高临床适用性的建议[信函]
J Inflamm Res. 2024 Dec 28;17:11755-11756. doi: 10.2147/JIR.S510503. eCollection 2024.
2
Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post-marketing surveillance in Japan.乌司奴单抗治疗克罗恩病的安全性和有效性：日本上市后监测的中期结果。
J Gastroenterol Hepatol. 2021 Nov;36(11):3069-3076. doi: 10.1111/jgh.15600. Epub 2021 Jul 22.
3
STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN.STEP-CD 研究：乌司奴单抗在儿童克罗恩病中的应用——来自 ESPGHAN 儿童 IBD 波尔图小组的多中心回顾性研究。
Eur J Pediatr. 2024 Aug;183(8):3253-3262. doi: 10.1007/s00431-024-05588-2. Epub 2024 May 3.
4
The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.优特克单抗在曾使用抗肿瘤坏死因子药物的克罗恩病患者中的长期临床疗效
Cureus. 2022 Aug 29;14(8):e28536. doi: 10.7759/cureus.28536. eCollection 2022 Aug.
5
One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.乌司奴单抗治疗克罗恩病患者的1年安全性和有效性：K-STAR研究
Inflamm Bowel Dis. 2025 May 12;31(5):1306-1316. doi: 10.1093/ibd/izae171.
6
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.用于诱导克罗恩病缓解的抗IL-12/23 p40抗体
Cochrane Database Syst Rev. 2016 Nov 25;11(11):CD007572. doi: 10.1002/14651858.CD007572.pub3.
7
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.比较乌司奴单抗和维得利珠单抗治疗对肿瘤坏死因子治疗应答不佳的克罗恩病患者的短期和长期疗效。
Aliment Pharmacol Ther. 2021 Jun;53(12):1289-1299. doi: 10.1111/apt.16377. Epub 2021 Apr 28.
8
Elderly-onset Crohn's disease remarkably responsive to ustekinumab: a case report.老年发病的克罗恩病对乌司奴单抗反应显著：一例报告。
Int J Colorectal Dis. 2020 Feb;35(2):355-359. doi: 10.1007/s00384-019-03476-y. Epub 2019 Dec 17.
9
Long-term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti-tumor necrosis factor failure.乌司奴单抗治疗抗肿瘤坏死因子治疗失败的儿童克罗恩病的长期临床及内镜结果
J Gastroenterol Hepatol. 2025 Jan;40(1):123-132. doi: 10.1111/jgh.16790. Epub 2024 Nov 4.
10
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.优特克单抗治疗克罗恩病的真实世界有效性和安全性：苏格兰优特克单抗队列研究
J Gastroenterol Hepatol. 2021 Aug;36(8):2067-2075. doi: 10.1111/jgh.15390. Epub 2021 Mar 5.

本文引用的文献

1
Application of Isokinetic Dynamometry Data in Predicting Gait Deviation Index Using Machine Learning in Stroke Patients: A Cross-Sectional Study.等速动力学数据在基于机器学习的脑卒中患者步态偏差指数预测中的应用：一项横断面研究。
Sensors (Basel). 2024 Nov 13;24(22):7258. doi: 10.3390/s24227258.
2
Prediction of the Short-Term Effectiveness of Ustekinumab in Patients with Moderate to Severe Crohn's Disease.乌司奴单抗治疗中重度克罗恩病患者短期疗效的预测
J Inflamm Res. 2024 Nov 20;17:9181-9191. doi: 10.2147/JIR.S479618. eCollection 2024.
3
Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病和炎症性肠病中的应用。
Aliment Pharmacol Ther. 2024 Sep;60(5):620-632. doi: 10.1111/apt.18138. Epub 2024 Jun 27.
4
Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.意大利溃疡性结肠炎和克罗恩病的真实世界治疗模式和医疗资源利用情况。
Adv Ther. 2024 Jun;41(6):2282-2298. doi: 10.1007/s12325-024-02840-x. Epub 2024 Apr 15.
5
The Effect of Renin-Angiotensin-Aldosterone System Blocking Agents on the Long-term Disease Course of Patients With Crohn's Disease.肾素-血管紧张素-醛固酮系统阻滞剂对克罗恩病患者长期病程的影响。
J Clin Gastroenterol. 2024;58(5):454-463. doi: 10.1097/MCG.0000000000001881. Epub 2023 Jun 26.
6
Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.阿奇霉素和甲硝唑与甲硝唑为基础的治疗方案在诱导轻中度儿科克罗恩病缓解中的比较：一项随机对照试验。
Gut. 2019 Feb;68(2):239-247. doi: 10.1136/gutjnl-2017-315199. Epub 2018 Feb 2.